Amer Zeidan: Can Early Blood Count Changes Predict Imetelstat Response in Lower Risk MDS?
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Cancer Journal:
“Our newest paper on association between early neutropenia and thrombocytopenia with subsequent clinical response to imetelstat in lower risk MDS.”
Title: Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Authors: Amer M. Zeidan, Valeria Santini, María Díez-Campelo, Michael R. Savona, Mikkael A. Sekeres, Yazan F. Madanat, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, David Valcárcel, Anna Jonášová, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Tymara Berry, Uwe Platzbecker and Rami S. Komrokji
Stay updated on all scientific advances Hemostasis Today.
-
Apr 21, 2026, 08:49Giacomo Buso: Global Collaboration in Vascular Medicine at the XI ESVM Congress 2026
-
Apr 21, 2026, 08:26Rehan Raina: Did You Know Your Immune Cells are What Actually Kill Cancer?
-
Apr 20, 2026, 18:59Chokri Ben Lamine: Contributing to a Landmark Chapter on Amegakaryocytic Thrombocytopenia in Bone Marrow Failure
-
Apr 20, 2026, 18:39David McIntosh: A Watershed Moment for Global Plasma Community and Call for Unified Action
-
Apr 20, 2026, 18:15Nandini Pethe: Grateful for a Fantastic 2026 HFA Symposium Filled with Impactful Educational Sessions and Meaningful Connections
-
Apr 20, 2026, 17:13Armghan Ans: The Stroke Decision Nobody Owns
-
Apr 20, 2026, 17:12Assefa Desalew: RhD-Negative Status and Adverse Perinatal Outcomes in Eastern Ethiopia
-
Apr 20, 2026, 16:55Francesco Lo Monaco: Blood Type and Heart Risk – Small Differences, Bigger Role of Lifestyle
-
Apr 20, 2026, 16:44Supporting the Next Generation in Thrombosis and Hemostasis at ISTH 2026